

IN THE CLAIMS

1-58. (Previously Canceled)
59-131. (Previously Canceled)
132-136. (Presently Canceled)
137. (Previously Canceled)
138. (Presently Canceled)
139. (Previously Canceled)
140. (Presently Canceled)
141. (Previously Canceled)
142. (Presently Canceled)
143. (Previously Canceled)
144. (Presently Canceled)
145. (Previously Canceled)
146. (Presently Canceled)
147. (Previously Canceled)
148. (Presently Canceled)
149. (Previously Canceled)
150. (Presently Canceled)
151. (Previously Canceled)
152. (Presently Canceled)
153. (Previously Canceled)
154-155. (Presently Canceled)
156. (Previously Canceled)
157. (Presently Canceled)
158. (Previously Canceled)
159. (Presently Canceled)
160. (Previously Canceled)
161-165. (Presently Canceled)

166-167. (Previously Canceled)
168-169. (Presently Canceled)
170. (Previously Canceled)
171. (Presently Canceled)
172. (Previously Canceled)
171. (Presently Canceled)
174. (Previously Canceled)
173-178. (Presently Canceled)
179. (Previously Canceled)
180-181. (Presently Canceled)
182. (Previously Canceled)
183. (Presently Canceled)
184. (Previously Canceled)
185. (Presently Canceled)
186. (Previously Canceled)
187-189. (Presently Canceled)
190. (Previously Canceled)
191-192. (Presently Canceled)
193. (Previously Canceled)
194. (Presently Canceled)
195. (Previously Canceled)
196. (Presently Canceled)
197. (Previously Canceled)
198-201. (Presently Canceled)
202. (Previously Canceled)
203. (Presently Canceled)
204. (Previously Canceled)
205. (Presently Canceled)
206. (Previously Canceled)

207-208. (Presently Canceled)
209. (Previously Canceled)
210-213. (Presently Canceled)
214. (Previously Canceled)
215-216. (Presently Canceled)
217. (Previously Canceled)
218. (Presently Canceled)
219. (Previously Canceled)
220. (Presently Canceled)
221. (Previously Canceled)
222-224. (Presently Canceled)
225. (Previously Canceled)
226-227. (Presently Canceled)
228. (Previously Canceled)
229. (Presently Canceled)
230. (Previously Canceled)
231. (Presently Canceled)
232. (Previously Canceled)
233-235. (Presently Canceled)
236. (Previously Canceled)
236-238. (Presently Canceled)
239. (Previously Canceled)
240. (Presently Canceled)
241. (Previously Canceled)
242. (Presently Canceled)
243-244. (Previously Canceled)
245-251. (Presently Canceled)

252. (Previously Presented): A substantially purified scFv antibody comprising the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2442.

253. (Previously Canceled)

254. (Presently Canceled)

255. (Previously Canceled)

256-264. (Presently Canceled)

265. (New): An antibody or antigen binding portion thereof which immunospecifically binds to SEQ ID NO:3, wherein the antibody or antigen binding portion thereof comprises:

- a) a variable heavy (VH) complementary determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:61 or an amino acid sequence of a VH CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2442;
- b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:62 or an amino acid sequence of a VH CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2442;
- c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:63 or an amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2442;
- d) a variable light (VL) CDR1 comprising the amino acid sequence of SEQ ID NO:64 or an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2442;
- e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:65 or an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2442; and
- f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:66 or an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2442.

266. (New): The antibody of claim 265, wherein the antibody is a monoclonal antibody.

267. (New): The antibody of claim 265, wherein the antibody is a human antibody.

268. (New): The antibody of claim 265, wherein the antibody is a humanized antibody.

269. (New): The antibody of claim 265, wherein the antibody is a Fab fragment.

270. (New): The antibody of claim 265, wherein the antibody is a F(ab')₂ fragment.

271. (New): The antibody of claim 265, wherein the antibody is an scFv.

272. (New): The antibody of claim 265, wherein the antibody is conjugated to a therapeutic or drug moiety.

273. (New): The antibody of claim 272, wherein the therapeutic or drug moiety is selected from the group consisting of a cytotoxin, a therapeutic agent or a radioactive metal ion.

274. (New): The antibody of claim 265, wherein the antibody is conjugated to a detectable substance.

275. (New): The antibody of claim 274, wherein the detectable substance is selected from the group consisting of an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.

276. (New): A kit comprising an antibody or fragment thereof as in any one of claims 265 or 274 and instructions for use.

277. (New): A pharmaceutical composition comprising an antibody according to any one of claims 265 or 272 and a pharmaceutically acceptable carrier.